· Funding and organization of health care, focus on pharmaceuticals

· HTA (Health Technology Assessment) characteristics, definition

· Health economics and pharmacoeconomics

· Regulatory processes: marketing authorization vs. reimbursement and patient access

· Clinical evidence interpretation (clinical studies, meta-analyses, indirect comparisons)

· Evidence hierarchy, sources of evidence-base medicine

· Range of clinical outcomes: from surrogates to QALY (Quality-Adjusted Life-Year)

· Pharmacoeconomic modelling: reasons, approaches, methods

· Integrations of various evidence types (clinical, economic) in complex HTA report

· In practice lessons the abovementioned topics are discussed and exercised using real-world model examples in pharmacotherapy of osteoporosis and diabetes